Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin 10% - Octapharma

Next Previous
Drug Profile

Immune globulin 10% - Octapharma

Alternative Names: 10% high purity immunoglobulin; 10% IVIG; Immune globulin 10%; Immunoglobulin - Octapharma; NewGam; Newnorm; octagam 10%; Octagam® Immune Globulin Intravenous (Human) 10% Liquid Preparation; Panzyga

Latest Information Update: 16 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Octapharma
  • Class Anti-infectives; Anti-inflammatories; Antiarrhythmics; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-peptide inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dermatomyositis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Dermatomyositis; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders
  • Phase III COVID 2019 infections; Obsessive-compulsive disorders
  • Discontinued Alzheimer's disease

Most Recent Events

  • 16 Jun 2026 Phase-III clinical trials in Immunodeficiency disorders in Czech Republic and Spain (IV) (NCT04502030)
  • 10 Jun 2026 Octapharma initiates the phase III PROTECT trial for Agammaglobulinaemia in USA (IV) (NCT07220915)
  • 28 Oct 2025 Octapharma plans a phase III trial for Autoimmune disorders, Agammaglobulinaemia and Rheumatic disorders (IV, Infusion) in December 2025 (NCT07220915)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top